Ann Pediatr Endocrinol Metab.  2012 Sep;17(3):160-168. 10.6065/apem.2012.17.3.160.

Changes in the Predicted Adult Height after Gonadotropin-Releasing Hormone Agonist Treatment in Girls with Idiopathic True Precocious Puberty

• Kwon EB
• Lee SJ
• Cha M
• Kim SY

• KMID: 1434710
• DOI: http://doi.org/10.6065/apem.2012.17.3.160

Abstract

PURPOSE
We evaluated the effects of the timing of treatment initiation with gonadotropin-releasing hormone agonist (GnRHa) on the change in predicted adult height (PAH) in girls with idiopathic true precocious puberty (TPP).
METHODS
Data for this retrospective study were collected on 104 girls with TPP who were treated with GnRHa for 36 months, between January 2002 and March 2012.
RESULTS
The PAH SDS differed before and after treatment in all patients (-1.91 +/- 1.47 vs. -1.37 +/- 1.17 after 1 year of treatment, -1.96 +/- 1.58 vs. -0.48 +/- 1.11 after 3 years of treatment) as well as in Group 1 (-2.15 +/- 1.54 vs. -1.51 +/- 1.20 after 1 year of treatment, -2.09 +/- 1.59 vs. -0.55 +/- 1.19 after 3 years of treatment) and Group 2 (-1.57 +/- 1.34 vs. -1.17 +/- 1.12 after 1 year of treatment, -1.50 +/- 1.55 vs. -0.21 +/- 0.74 after 3 years of treatment). This result could be due to improvement in bone age advancement during the treatment. The difference between mid-parental height SDS and PAH SDS was decreased after GnRHa treatment. However, the means of PAH SDS did not surpass the mid-parental height SDS.
CONCLUSION
GnRHa treatment can preserve growth potential by slowing bone age progression, resulting in short adult height, but it cannot alter the genetic growth potential.

Keyword

Puberty, precocious; Gonadotropin-releasing hormone; height

MeSH Terms

Adult
Gonadotropin-Releasing Hormone
Humans
Puberty, Precocious
Retrospective Studies
Gonadotropin-Releasing Hormone